RT Journal Article
SR Electronic
T1 Clinicians should assess the benefits and risks of using bezlotoxumab for reducing the risk of recurrent <em>Clostridium difficile</em> infection
JF Evidence Based Medicine
JO Evid Based Med
FD BMJ Publishing Group Ltd
SP 150
OP 151
DO 10.1136/ebmed-2017-110722
VO 22
IS 4
A1 Habiba Hassouna
A1 Abhishek Deshpande
YR 2017
UL http://ebm.bmj.com/content/22/4/150.abstract
AB